John Eikelboom

Summary

Affiliation: McMaster University
Country: Canada

Publications

  1. doi request reprint Mandatory contrast-enhanced venography to detect deep-vein thrombosis (DVT) in studies of DVT prophylaxis: upsides and downsides
    Jack Hirsh
    John W Eikelboom, Department of Medicine, McMaster University, Hamilton General Hospital, 237 Barton Street East, Hamilton, Ontario, L8L 2X2, Canada, E mail
    Thromb Haemost 111:10-3. 2014
  2. doi request reprint Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation
    John W Eikelboom
    Population Health Research Institute, McMaster University, 237 Barton St East, Hamilton, Ontario, Canada
    J Am Coll Cardiol 62:900-8. 2013
  3. doi request reprint Antithrombotic therapy for stroke prevention in atrial fibrillation and mechanical heart valves
    John W Eikelboom
    Department of Medicine, McMaster University, Hamilton, ON, Canada
    Am J Hematol 87:S100-7. 2012
  4. pmc Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
    John W Eikelboom
    Department of Medicine, McMaster University, Hamilton, ON, L9K 1H8, Canada
    Chest 141:e89S-119S. 2012
  5. pmc The effect of long-term homocysteine-lowering on carotid intima-media thickness and flow-mediated vasodilation in stroke patients: a randomized controlled trial and meta-analysis
    Kathleen Potter
    School of Medicine and Pharmacology, University of Western Australia, Perth, Australia
    BMC Cardiovasc Disord 8:24. 2008
  6. doi request reprint Major bleeding, mortality, and efficacy of fondaparinux in venous thromboembolism prevention trials
    John W Eikelboom
    Thromboembolism Unit, Hamilton General Hospital, Hamilton, Ontario, L8L 2X2, Canada
    Circulation 120:2006-11. 2009
  7. pmc Aspirin resistance and its implications in clinical practice
    John Eikelboom
    McMaster University, Hamilton, Ontario, Canada
    MedGenMed 7:76. 2005
  8. ncbi request reprint Duration of anticoagulant therapy for venous thromboembolism
    Nina C Raju
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Med J Aust 190:659-60. 2009
  9. doi request reprint Selective factor Xa inhibition for thromboprophylaxis
    John W Eikelboom
    McMaster University, Hamilton, ON, Canada
    Lancet 372:6-8. 2008
  10. doi request reprint Guidelines for anticoagulant use in acute coronary syndromes
    John Eikelboom
    Thrombosis Service, Hamilton General Hospital, Hamilton, Ont, Canada, L8L 2X2
    Lancet 371:1559-61. 2008

Detail Information

Publications109 found, 100 shown here

  1. doi request reprint Mandatory contrast-enhanced venography to detect deep-vein thrombosis (DVT) in studies of DVT prophylaxis: upsides and downsides
    Jack Hirsh
    John W Eikelboom, Department of Medicine, McMaster University, Hamilton General Hospital, 237 Barton Street East, Hamilton, Ontario, L8L 2X2, Canada, E mail
    Thromb Haemost 111:10-3. 2014
    ..Therefore when used as a measure of efficacy in trials of thromboprophylaxis, venography has limitations for comparing the relative effects of alternative antithrombotic agents on outcomes important to patients...
  2. doi request reprint Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation
    John W Eikelboom
    Population Health Research Institute, McMaster University, 237 Barton St East, Hamilton, Ontario, Canada
    J Am Coll Cardiol 62:900-8. 2013
    ..This study sought to compare the net clinical benefit of dabigatran 110 mg bid and 150 mg bid with that of warfarin in patients with atrial fibrillation (AF)...
  3. doi request reprint Antithrombotic therapy for stroke prevention in atrial fibrillation and mechanical heart valves
    John W Eikelboom
    Department of Medicine, McMaster University, Hamilton, ON, Canada
    Am J Hematol 87:S100-7. 2012
    ....
  4. pmc Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
    John W Eikelboom
    Department of Medicine, McMaster University, Hamilton, ON, L9K 1H8, Canada
    Chest 141:e89S-119S. 2012
    ....
  5. pmc The effect of long-term homocysteine-lowering on carotid intima-media thickness and flow-mediated vasodilation in stroke patients: a randomized controlled trial and meta-analysis
    Kathleen Potter
    School of Medicine and Pharmacology, University of Western Australia, Perth, Australia
    BMC Cardiovasc Disord 8:24. 2008
    ..B-vitamin supplements reduce tHcy and improve endothelial function in short term trials, but the long-term effects of the treatment on vascular structure and function are unknown...
  6. doi request reprint Major bleeding, mortality, and efficacy of fondaparinux in venous thromboembolism prevention trials
    John W Eikelboom
    Thromboembolism Unit, Hamilton General Hospital, Hamilton, Ontario, L8L 2X2, Canada
    Circulation 120:2006-11. 2009
    ....
  7. pmc Aspirin resistance and its implications in clinical practice
    John Eikelboom
    McMaster University, Hamilton, Ontario, Canada
    MedGenMed 7:76. 2005
    ....
  8. ncbi request reprint Duration of anticoagulant therapy for venous thromboembolism
    Nina C Raju
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Med J Aust 190:659-60. 2009
    ..The risk of bleeding, as well as patient preferences, must be considered when deciding duration of warfarin therapy...
  9. doi request reprint Selective factor Xa inhibition for thromboprophylaxis
    John W Eikelboom
    McMaster University, Hamilton, ON, Canada
    Lancet 372:6-8. 2008
  10. doi request reprint Guidelines for anticoagulant use in acute coronary syndromes
    John Eikelboom
    Thrombosis Service, Hamilton General Hospital, Hamilton, Ont, Canada, L8L 2X2
    Lancet 371:1559-61. 2008
  11. ncbi request reprint Combined antiplatelet and anticoagulant therapy: clinical benefits and risks
    J W Eikelboom
    Thrombosis Service, Hamilton General Hospital, Hamilton, ON, Canada
    J Thromb Haemost 5:255-63. 2007
    ..Whether the benefits of triple therapy outweigh the risks in patients with atrial fibrillation and coronary stents requires evaluation in randomized trials...
  12. ncbi request reprint Monitoring unfractionated heparin with the aPTT: time for a fresh look
    John W Eikelboom
    Thrombosis Service, Hamilton General Hospital, Hamilton Health Sciences Corporation and McMaster University, Hamilton, Ontario, Canada
    Thromb Haemost 96:547-52. 2006
    ..However, currently available unfractionated heparin assays are much more expensive than the aPTT, are not widely available, and their validity has not been adequately assessed in clinical outcome studies...
  13. ncbi request reprint Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial
    J W Eikelboom
    Department of Medicine, HGH McMaster Clinic, McMaster University, Hamilton, Ontario, Canada
    J Thromb Haemost 3:2649-55. 2005
    ....
  14. doi request reprint Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment
    John W Eikelboom
    Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada L8L 2X2
    Am Heart J 159:348-353.e1. 2010
    ..Apixaban may be an attractive alternative to ASA for prevention of stroke in patients with AF who cannot or will not take a VKA...
  15. ncbi request reprint Adverse impact of bleeding on prognosis in patients with acute coronary syndromes
    John W Eikelboom
    Thrombosis Service, Hamilton Health Sciences, Hamilton, Ontario, Canada
    Circulation 114:774-82. 2006
    ..The use of multiple antithrombotic drugs and aggressive invasive strategies has increased the risk of major bleeding in acute coronary syndrome (ACS) patients. It is not known to what extent bleeding determines clinical outcome...
  16. doi request reprint Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial
    John W Eikelboom
    Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada
    Circulation 123:2363-72. 2011
    ..The purpose of this study was to compare their risks of bleeding in the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial...
  17. doi request reprint Duration of red cell storage before transfusion and in-hospital mortality
    John W Eikelboom
    Department of Medicine, McMaster University, Ontario, Canada
    Am Heart J 159:737-743.e1. 2010
    ..The objective of the study was to examine the association between duration of pretransfusion storage of red cells and in-hospital mortality...
  18. doi request reprint Apixaban in patients with atrial fibrillation
    Stuart J Connolly
    Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
    N Engl J Med 364:806-17. 2011
    ..Apixaban, a novel factor Xa inhibitor, may be an alternative treatment for such patients...
  19. ncbi request reprint Beyond unfractionated heparin and warfarin: current and future advances
    Jack Hirsh
    Henderson Research Centre, Hamilton Health Sciences Corporatin, Ontario, Canada
    Circulation 116:552-60. 2007
  20. doi request reprint Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study
    Eloi Marijon
    Paris Cardiovascular Research Center, Paris, France E M Paris Descartes University, Paris, France E M, J Y L H European Georges Pompidou Hospital, Paris, France E M, J Y L H Population Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, ON, Canada S C, S Y, J P, J E, E T, S Y Boehringer Ingelheim Pharma GmbH and Co KG, Clinical Development and Medical Affairs, Ingelheim am Rhein, Germany, and Medical Faculty Mannheim of the University of Heidelberg, Heidelberg, Germany M B Cardiovascular Research Foundation and Thomas Jefferson Medical College, New York, NY M E and Uppsala Clinical Research Centre, University Hospital, Uppsala, Sweden L W
    Circulation 128:2192-201. 2013
    ..Atrial fibrillation is associated with increased mortality, but the specific causes of death and their predictors have not been described among patients on effective anticoagulant therapy...
  21. doi request reprint The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study
    Stuart J Connolly
    Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton
    Circulation 128:237-43. 2013
    ..There is a need for longer-term follow-up of patients on dabigatran and for further data comparing the 2 dabigatran doses...
  22. doi request reprint Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial
    Jeff S Healey
    Population Health Research Institute, McMaster University, Hamilton, Canada
    Circulation 126:343-8. 2012
    ..Dabigatran reduces ischemic stroke in comparison with warfarin; however, given the lack of antidote, there is concern that it might increase bleeding when surgery or invasive procedures are required...
  23. doi request reprint Dabigatran versus warfarin in patients with atrial fibrillation
    Stuart J Connolly
    Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
    N Engl J Med 361:1139-51. 2009
    ..Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin inhibitor...
  24. doi request reprint Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range
    Stuart J Connolly
    Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada
    Circulation 118:2029-37. 2008
    ..This report examines how differences in time in therapeutic range (TTR) between centers and between countries affect the outcomes of OAC therapy...
  25. ncbi request reprint Oral anticoagulant and antiplatelet therapy and peripheral arterial disease
    Sonia Anand
    McMaster University, Hamilton, ON, Canada
    N Engl J Med 357:217-27. 2007
    ..Antiplatelet drugs reduce this risk, but the role of oral anticoagulant agents in the prevention of cardiovascular complications in patients with peripheral arterial disease is unclear...
  26. doi request reprint New anticoagulants for atrial fibrillation
    Magdalena Sobieraj-Teague
    McMaster University, Hamilton, Ontario, Canada
    Semin Thromb Hemost 35:515-24. 2009
    ..A new vitamin K antagonist (ATI-5923) with improved pharmacological properties compared with warfarin is also being evaluated in a phase III trial. None of the new agents have as yet been approved for clinical use...
  27. pmc Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa)
    Stuart J Connolly
    Population Health Research Institute, 237 Barton Street East, Hamilton, Ontario, Canada
    Eur Heart J 34:1498-505. 2013
    ..Patients with atrial fibrillation (AF) are at increased risk of stroke. Betrixaban is a novel oral factor Xa inhibitor administered once daily, mostly excreted unchanged in the bile and with low (17%) renal excretion...
  28. doi request reprint Genetic determinants of dabigatran plasma levels and their relation to bleeding
    Guillaume Pare
    Population Health Research Institute, Hamilton Health Sciences and McMaster University, David Braley Cardiac Vascular and Stroke Research Institute, 237 Barton St E, Room C3 103, Hamilton, ON, Canada L8L 2X2
    Circulation 127:1404-12. 2013
    ..We hypothesized that genetic variants could contribute to interindividual variability in blood concentrations of the active metabolite of dabigatran etexilate and influence the safety and efficacy of dabigatran...
  29. ncbi request reprint Challenges of establishing new antithrombotic therapies in atrial fibrillation
    Stuart J Connolly
    Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada
    Circulation 116:449-55. 2007
  30. doi request reprint Pacemaker-detected atrial fibrillation in patients with pacemakers: prevalence, predictors, and current use of oral anticoagulation
    Jeff S Healey
    Population Health Research Institute, Hamilton, Ontario, Canada
    Can J Cardiol 29:224-8. 2013
    ..This study sought to determine the prevalence and predictors of pacemaker-detected AF and to document current oral anticoagulant use...
  31. ncbi request reprint Aspirin resistance: does it exist and is it an important clinical problem?
    John Eikelboom
    Thrombosis Service, Hamilton General Hospital
    Clin Adv Hematol Oncol 4:268-70. 2006
  32. ncbi request reprint New oral anticoagulants: not quite there yet
    Ganesan Karthikeyan
    Department of Medicine, McMaster University, Hamilton, ON, Canada
    Pol Arch Med Wewn 119:53-8. 2009
    ..In this review, we attempt to provide a balanced perspective on the relative merits and demerits of the new, orally active anticoagulants, and speculate on the future of these agents in clinical practice...
  33. doi request reprint Use of clopidogrel post-coronary artery bypass surgery in canadian patients with acute coronary syndromes
    Ahmed Krimly
    Terrence Donnelly Heart Centre, St Michael s Hospital, University of Toronto, Toronto, Ontario, Canada
    Can J Cardiol 27:711-5. 2011
    ....
  34. doi request reprint New pharmacotherapy for stroke prevention in atrial fibrillation: update 2010
    Luciana Armaganijan
    Department of Medicine, Cardiology Division, Arrhythmia Service, McMaster University, HHSC, David Braley CVSRI, Hamilton, Ontario, Canada
    Adv Ther 26:1058-71. 2009
    ..This review focuses on new antithrombotic therapies for stroke prevention in patients with AF...
  35. doi request reprint Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6
    Ganesan Karthikeyan
    Hamilton General Hospital, 237 Barton Street East, Hamilton, Ontario, Canada
    Expert Rev Cardiovasc Ther 7:241-9. 2009
    ..This clinical trial report discusses the findings of these two pivotal trials...
  36. doi request reprint Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future
    Nina C Raju
    Thrombosis Service, Hamilton General Hospital, 237 Barton Street East, Hamilton, ON L8L2X2, Canada
    Nat Clin Pract Cardiovasc Med 5:766-80. 2008
    ..The nonthienopyridine P2Y(12) inhibitors AZD6140 and cangrelor are presently being evaluated in phase III, randomized, controlled trials...
  37. doi request reprint Antiplatelet therapy and cardiac surgery: review of recent evidence and clinical implications
    David Fitchett
    Division of Cardiology, St Michael s Hospital, University of Toronto, Toronto, Ontario, Canada
    Can J Cardiol 29:1042-7. 2013
    ..Recent studies have suggested the value of preoperative in vitro platelet aggregometry to determine perioperative bleeding risk...
  38. doi request reprint Postoperative low-molecular-weight heparin bridging is associated with an increase in wound hematoma following surgery for pacemakers and implantable defibrillators
    Marlene Robinson
    Department of Medicine, McMaster University, 237 Barton Street East, Hamilton, Ontario, Canada
    Pacing Clin Electrophysiol 32:378-82. 2009
    ..Low-molecular-weight heparin (LMWH) is often used; however, wound hematoma is a common complication...
  39. ncbi request reprint Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials
    John W Eikelboom
    General Division, Hamilton Health Sciences, Hamilton, Ontario, Canada
    Circulation 112:3855-67. 2005
    ..There is uncertainty about the role of intravenous unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) in patients with ST-elevation myocardial infarction (STEMI) treated with aspirin and thrombolysis...
  40. doi request reprint Point-of-care testing for assessment of adequacy of oral antiplatelet therapy in patients with cardiovascular disease
    Magdalena Sobieraj-Teague
    Hamilton Health Sciences, McMaster University, Hamilton, Ontario L8L 2X2, Canada
    Future Cardiol 6:289-99. 2010
    ....
  41. doi request reprint New antithrombotic agents--insights from clinical trials
    Jeremy S Paikin
    Department of Medicine, McMaster University, Hamilton General Hospital, 237 Barton Street East, Hamilton, Ontario, Canada
    Nat Rev Cardiol 7:498-509. 2010
    ..In this article, we review these new antithrombotic agents and provide plausible explanations for the results of phase III randomized controlled trials of these drugs...
  42. doi request reprint Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial
    Shamir R Mehta
    McMaster University and Population Health Research Institute, Hamilton Health Sciences, Hamilton, ON, Canada
    Lancet 376:1233-43. 2010
    ..We assessed the effect of various clopidogrel and aspirin regimens in prevention of major cardiovascular events and stent thrombosis in patients undergoing PCI...
  43. doi request reprint Effects of CYP2C19 genotype on outcomes of clopidogrel treatment
    Guillaume Pare
    Population Health Research Institute, Hamilton Health Sciences, Hamilton, ON, Canada
    N Engl J Med 363:1704-14. 2010
    ....
  44. ncbi request reprint Role of triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents
    Jeremy S Paikin
    McMaster University, Hamilton, Ontario, Canada
    Med J Aust 192:487-8. 2010
    ..Decisions regarding the use of triple therapy should take into account the balance between thromboembolism and bleeding risk in individual patients...
  45. ncbi request reprint Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial
    Shamir R Mehta
    Department of Medicine, McMaster University and Population Health Research Institute, Hamilton Health Sciences, Hamilton, Ontario, Canada
    J Am Coll Cardiol 50:1742-51. 2007
    ..This study reports a prospectively planned analysis of patients with acute coronary syndrome who underwent early percutaneous coronary intervention (PCI) in the OASIS-5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial...
  46. doi request reprint Antiplatelet therapy for secondary prevention of noncardioembolic ischemic stroke: a critical review
    MARTIN J O'DONNELL
    McMaster University, Ontario, Canada
    Stroke 39:1638-46. 2008
    ....
  47. doi request reprint Mortality and morbidity following a major bleed in a registry population with acute ST elevation myocardial infarction
    Shoaib Amlani
    Department of Medicine, McMaster University, 237 Barton Street East, Hamilton, ON L8L 2X2, Canada
    J Thromb Thrombolysis 30:434-40. 2010
    ..Therapies that maintain efficacy while reducing bleeding and that reduce the risk of death in patients who develop bleeding are needed...
  48. doi request reprint Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial
    Jon David R Schwalm
    Department of Medicine, Division of Cardiology, Hamilton Health Sciences and McMaster University, 5th Floor, McMaster Clinic, 237 Barton Street East, Hamilton, ON L8L 2X2, Canada
    J Thromb Thrombolysis 30:127-32. 2010
    ..The purpose of this study is to assess the feasibility of evaluating the added benefit and safety of triple therapy (TT-warfarin, ASA, and clopidogrel) versus dual therapy (DT-ASA and clopidogrel) in patients at risk of LVT post aSTEMI...
  49. doi request reprint Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Ass
    Shamir R Mehta
    McMaster University, Population Health Research Institute, Hamilton Health Sciences, Hamilton, Ontario, Canada
    Circulation 118:2038-46. 2008
    ..Combined results for these 2 trials on major efficacy and safety outcomes and data on the effects of fondaparinux in relation to interventional management strategy have not been previously reported...
  50. doi request reprint The effect of pre-operative aspirin on bleeding, transfusion, myocardial infarction, and mortality in coronary artery bypass surgery: a systematic review of randomized and observational studies
    Jack C J Sun
    Division of Cardiac Surgery, Hamilton General Hospital, McMaster University, 237 Barton St E, Hamilton, Ontario, Canada L8L 2X2
    Eur Heart J 29:1057-71. 2008
    ..To obtain estimates of the efficacy and safety of pre-operative aspirin in patients undergoing coronary artery bypass grafting (CABG)...
  51. doi request reprint Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends
    Jack C J Sun
    Division of Cardiac Surgery, McMaster University, Hamilton, ON, Canada
    Lancet 374:565-76. 2009
    ....
  52. ncbi request reprint Short-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of prospective studies investigating symptomatic outcomes
    James D Douketis
    Department of Medicine, McMaster University, and St Joseph s Hospital, Hamilton, Ontario, Canada L8N 4A6
    Arch Intern Med 162:1465-71. 2002
    ....
  53. ncbi request reprint Congestive heart failure complicating non-ST segment elevation acute coronary syndrome: incidence, predictors, and clinical outcomes
    Shamir R Mehta
    Department of Medicine, Mc Master University, Hamilton Health Sciences, Hamilton, ON, Canada
    Can J Physiol Pharmacol 83:98-103. 2005
    ..Despite this worse prognosis, patients with ACS developing CHF are less likely to be referred for invasive management...
  54. ncbi request reprint Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency
    Wendy Lim
    McMaster University and Hamilton General Hospital, Hamilton, Ontario, Canada
    Ann Intern Med 144:673-84. 2006
    ....
  55. doi request reprint Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: the Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting study
    Jack C J Sun
    Division of Cardiac Surgery, McMaster University, Hamilton, Canada
    Am Heart J 160:1178-84. 2010
    ..We performed a pilot study measuring safety and efficacy outcomes of aspirin and clopidogrel therapy after CABG...
  56. doi request reprint American Association of Orthopedic Surgeons and American College of Chest Physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: what are the implications for clinicians and patients?
    John W Eikelboom
    Department of Medicine, McMaster University, Hamilton, ON, Canada
    Chest 135:513-20. 2009
    ....
  57. doi request reprint Prevention of thromboembolism in the patient with acute coronary syndrome and atrial fibrillation: the clinical dilemma of triple therapy
    David Fitchett
    aSt Michael s Hospital bSouthlake Hospital, Newmarket cHamilton General Hospital, McMaster University, Hamilton dSunnybrook Hospital, University of Toronto eUniversity of Toronto, Toronto, Ontario, Canada
    Curr Opin Cardiol 29:1-9. 2014
    ....
  58. ncbi request reprint Platelet function testing: quality assurance
    Catherine P M Hayward
    Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
    Semin Thromb Hemost 33:273-82. 2007
    ..Quality assurance issues relevant to testing platelet function are reviewed in this article, with a focus on their application to established and to new and emerging tests...
  59. ncbi request reprint Nonbleeding complications of unfractionated and low-molecular weight heparins
    John Eikelboom
    Thrombosis Service, Hamilton General Hospital, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Clin Adv Hematol Oncol 5:871-3. 2007
  60. ncbi request reprint Management of antiphospholipid antibody syndrome: a systematic review
    Wendy Lim
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    JAMA 295:1050-7. 2006
    ..Patients with APS may be at increased risk of recurrent arterial or venous thrombosis or pregnancy loss...
  61. pmc Inherited thrombophilia and pregnancy associated venous thromboembolism
    Wendy Lim
    Department of Medicine, McMaster University, St Joseph s Hospital, Canada
    BMJ 334:1318-21. 2007
  62. doi request reprint Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk
    John W Eikelboom
    McMaster University, Hamilton, Ontario, Canada
    Circulation 118:1705-12. 2008
    ....
  63. doi request reprint Processed residual pump blood in cardiac surgery: the Processed Residual Blood in Cardiac surgery trial
    Richard Whitlock
    McMaster University, Hamilton, Ontario, Canada
    Transfusion 53:1487-92. 2013
    ..We sought to establish if processing residual CPB volume with ultrafiltration reduces homologous blood transfusion and bleeding...
  64. doi request reprint Underuse of evidence-based warfarin dosing methods for atrial fibrillation patients
    Robby Nieuwlaat
    Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada
    Thromb Res 125:e128-31. 2010
    ..We assessed to what extent generalist and specialist physicians use evidence-based methods for warfarin maintenance dosing...
  65. ncbi request reprint Thromboprophylaxis practice patterns in hip fracture surgery patients: experience in Perth, Western Australia
    Susan Wan
    School of Medicine and Pharmacology, University of Western Australia, Royal Perth Hospital, Perth, Western Australia, Australia
    ANZ J Surg 73:826-9. 2003
    ..The purpose of the present study was to examine current thromboprophylaxis practice patterns in patients undergoing hip fracture surgery at Royal Perth Hospital...
  66. ncbi request reprint Ximelagatran or warfarin for stroke prevention in patients with atrial fibrillation?
    Graeme J Hankey
    Stroke Unit, Royal Perth Hospital, 197 Wellington Street Perth, Australia 6001
    Stroke 35:389-91. 2004
  67. ncbi request reprint Is there a role for laboratory testing to identify patients at risk of aspirin treatment failure?
    Wai Khoon Ho
    Centre for Clinical Research Excellence, Department of Neurology and Department of Haematology, Royal Perth Hospital, Australia and School of Medicine and Pharmacology, University of Western Australia, Australia
    Blood Coagul Fibrinolysis 15:129-30. 2004
  68. ncbi request reprint Aspirin resistance: a new independent predictor of vascular events?
    John W Eikelboom
    Department of Haematology, Royal Perth Hospital, Wellington Street, Perth, WA 6001, Australia
    J Am Coll Cardiol 41:966-8. 2003
  69. ncbi request reprint Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials
    Daniel J Quinlan
    King s College Hospital, London, United Kingdom
    Ann Intern Med 140:175-83. 2004
    ..However, for patients who present with pulmonary embolism, the role of low-molecular-weight heparin is uncertain and unfractionated heparin remains widely used...
  70. pmc Aspirin resistance
    Graeme J Hankey
    BMJ 328:477-9. 2004
  71. ncbi request reprint Endothelial and platelet activation in acute ischemic stroke and its etiological subtypes
    Paul Cherian
    Department of Medicine, University of Western Australia, Perth, Australia
    Stroke 34:2132-7. 2003
    ..We also hypothesized that these markers would be differentially elevated in ischemic stroke caused by large- and small-artery atherothrombosis compared with cardiogenic embolism...
  72. ncbi request reprint Failure of aspirin to prevent atherothrombosis: potential mechanisms and implications for clinical practice
    John W Eikelboom
    Department of Haematology, Royal Perth Hospital, Box X2213 GPO, Perth, WA 6001, Australia
    Am J Cardiovasc Drugs 4:57-67. 2004
    ....
  73. ncbi request reprint Long-term management of venous thromboembolism: is there a role for low-intensity warfarin therapy?
    John W Eikelboom
    Med J Aust 179:68-9. 2003
    ..The recently released PREVENT trial provides some answers...
  74. ncbi request reprint Low molecular weight heparins and heparinoids
    John W Eikelboom
    Department of Haematology, Royal Perth Hospital, GPO Box X2213, Perth, WA 6001, Australia
    Med J Aust 177:379-83. 2002
    ..The heparinoid danaparoid sodium is effective for the treatment of heparin-induced thrombocytopenia...
  75. ncbi request reprint Antiplatelet drugs
    Graeme J Hankey
    Royal Perth Hospital, 197 Wellington Street, Perth, WA 6001, Australia
    Med J Aust 178:568-74. 2003
    ....
  76. ncbi request reprint Prevention of coronary heart disease with aspirin and clopidogrel: efficacy, safety, costs and cost-effectiveness
    Wai Khoon Ho
    Department of Haematology, Royal Perth Hospital, Perth, Australia
    Expert Opin Pharmacother 5:493-503. 2004
    ..g., > 20%/year). The combination of clopidogrel and aspirin should be considered in patients with non-ST-segment elevation acute coronary syndrome or undergoing percutaneous coronary intervention...
  77. ncbi request reprint Thromboprophylaxis practice patterns in two Western Australian teaching hospitals
    John W Eikelboom
    Department of Hematology, Royal Perth Hospital, Wellington Street, Perth, WA, 6001 Australia
    Haematologica 89:586-93. 2004
    ..Our objective was to determine what proportion of patients undergoing elective hip or knee arthroplasty actually receive recommended thromboprophylaxis according to international guidelines...
  78. ncbi request reprint A replacement for warfarin: the search continues
    John W Eikelboom
    Circulation 116:131-3. 2007
  79. ncbi request reprint Venous thromboembolism: diagnosis and management of deep venous thrombosis
    Wai Khoon Ho
    Royal Perth Hospital, Perth, WA
    Med J Aust 182:476-81. 2005
    ..The risk of recurrence is highest in people with recurrent unprovoked DVT or chronic predisposing factors (eg, cancer) who require indefinite anticoagulant treatment...
  80. ncbi request reprint Who is (still) getting HIT?
    Theodore E Warkentin
    Chest 131:1620-2. 2007
  81. ncbi request reprint Latest medical treatment strategies for venous thromboembolism
    Simon J McRae
    The Queen Elizabeth Hospital, Institute of Medical and Veterinary Sciences, Department of Haematology Oncology, 28 Woodville Rd, Woodville 5011, Adelaide, South Australia, Australia
    Expert Opin Pharmacother 8:1221-33. 2007
    ....
  82. pmc Anticoagulation for venous thromboembolism
    John W Eikelboom
    BMJ 334:645. 2007
  83. pmc Clinical update on the therapeutic use of clopidogrel: treatment of acute ST-segment elevation myocardial infarction (STEMI)
    Huyen Tran
    Department of Clinical Haematology, Monash Medical Centre, Victoria, Australia
    Vasc Health Risk Manag 2:379-87. 2006
    ..Thus, dual antiplatelet therapy with the combination of clopidogrel and aspirin is becoming the new standard of care for the management of patients with STEMI...
  84. ncbi request reprint Aspirin resistance
    Huyen A Tran
    Department of Clinical Haematology, Monash Medical Centre, Clayton, Victoria, Australia
    Thromb Res 120:337-46. 2007
    ....
  85. ncbi request reprint Guidelines for the management of acute coronary syndromes 2006
    John W Eikelboom
    Med J Aust 186:101; discussion 101-2. 2007
  86. ncbi request reprint The tissue factor pathway in ischemic stroke
    Murray J Adams
    Western Australian Biomedical Research Institute, School of Biomedical Sciences, Curtin University, Perth, Australia
    Blood Coagul Fibrinolysis 17:527-32. 2006
    ....
  87. ncbi request reprint Enoxaparin versus unfractionated heparin in ST-elevation myocardial infarction
    Peter Sleight
    N Engl J Med 354:2830-1; author reply 2831-2. 2006
  88. ncbi request reprint Adding aspirin to clopidogrel after TIA and ischemic stroke: benefits do not match risks
    Graeme J Hankey
    Stroke Unit, Department of Neurology, Royal Perth Hospital, Perth, Australia
    Neurology 64:1117-21. 2005
    ....
  89. ncbi request reprint Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events
    John W Eikelboom
    Department of Medicine, University of Western Australia, Thrombosis and Haemophilia Unit, Royal Perth Hospital, Perth, Australia
    Circulation 105:1650-5. 2002
    ..We studied whether aspirin resistance, defined as failure of suppression of thromboxane generation, increases the risk of cardiovascular events in a high-risk population...
  90. ncbi request reprint The beginning of the end of warfarin?
    John W Eikelboom
    Med J Aust 180:549-51. 2004
  91. ncbi request reprint Will prasugrel supersede clopidogrel for acute coronary syndromes?
    Graeme J Hankey
    Med J Aust 188:381-2. 2008
  92. ncbi request reprint Antiplatelet agents in acute coronary syndromes
    John W Eikelboom
    Department of Haematology, Royal Perth Hospital and Department of Medicine, University of Western Australia, Crawley, WA, Australia
    Semin Vasc Med 3:403-14. 2003
    ....
  93. ncbi request reprint Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials
    Susan Wan
    School of Medicine and Pharmacology, University of Western Australia, Perth, West Australia
    Circulation 110:744-9. 2004
    ..Randomized trials and meta-analyses have reached conflicting conclusions about the role of thrombolytic therapy for the treatment of acute pulmonary embolism...
  94. ncbi request reprint Recurrent palmar-plantar erythrodysaesthesia following high-dose cytarabine treatment for acute lymphoblastic leukemia
    Julie H Crawford
    Royal Perth Hospital, Perth, Western Australia, Australia
    Eur J Haematol 69:315-7. 2002
    ....
  95. ncbi request reprint Venous thromboembolism: diagnosis and management of pulmonary embolism
    Cindy H Lee
    Department of Haematology, Royal Perth Hospital, Perth, WA, Australia
    Med J Aust 182:569-74. 2005
    ....
  96. ncbi request reprint ESPRIT trial
    Martin O'Donnell
    Lancet 368:447; author reply 449. 2006
  97. ncbi request reprint Management of patients with acute coronary syndromes: what is the clinical role of direct thrombin inhibitors?
    John W Eikelboom
    Department of Medicine, Thrombosis and Haemophilia Unit, University of Western Australia, Royal Perth Hospital, Australia
    Drugs 62:1839-52. 2002
    ....
  98. ncbi request reprint Cyclooxygenase inhibitors and the antiplatelet effects of aspirin
    Andrew McQuillan
    N Engl J Med 346:1589-90; author reply 1589-90. 2002
  99. ncbi request reprint Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review
    Wai Khoon Ho
    Department of Haematology, Royal Perth Hospital and Centre for Clinical Research Excellence, University of Western Australia, Perth
    Arch Intern Med 166:729-36. 2006
    ..These data call into question the cost-effectiveness of routine testing for these common inherited thrombophilic polymorphisms among patients with a first episode of VTE...
  100. ncbi request reprint Adjunctive use of direct thrombin inhibitors in patients receiving fibrinolytic therapy for acute myocardial infarction
    John K French
    Cardiovascular Research Unit, Green Lane Hospital, Auckland, New Zealand
    Am J Cardiovasc Drugs 4:107-15. 2004
    ..The major benefit of direct thrombin inhibitors appears to be in patients undergoing PCI, particularly after STEMI...
  101. pmc Antithrombotic treatment for peripheral arterial disease
    Daniel G Hackam
    Division of Clinical Pharmacology and Toxicology, University of Toronto, Toronto, Canada
    Heart 93:303-8. 2007
    ..In addition, this disorder is associated with a systemic milieu characterised by ongoing platelet activation and heightened thrombogenesis...